Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.
Authors
Alessandra Anna Prete
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Alessandra Anna Prete , Paolo Manca , Federica Morano , Cosimo Rasola , Marco Messina , Vincenzo Formica , Domenico Cristiano Corsi , Enrico Cortesi , Giovanni Luca Frassineti , M. Giulia Zampino , Mariaelena Casagrande , Gianluca Masi , Monica Ronzoni , Mario Scartozzi , Michele Prisciandaro , Francesca Bergamo , Valentina Vettore , Filippo Pietrantonio , Matteo Fassan , Sara Lonardi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.005
Abstract #
5
Poster Bd #
A6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of baseline inflammatory biomarkers with outcomes in penile squamous cell carcinoma (pSCC) treated with immune checkpoint inhibitors (ICI).
First Author: Tony Zhuang
Poster
2020 ASCO Virtual Scientific Program
Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study.
First Author: Sara Lonardi
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville
Poster
2023 ASCO Annual Meeting
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
First Author: Rachel Frascati